MarketPeel
Insider Trading Intelligence
Pricing
…
EC

Eric Crombez

RARE
EVP AND CHIEF MEDICAL OFFICER · ULTRAGENYX PHARMACEUTICAL INC. · CIK 0001653052
FILING MIX · LIFETIME58%/42%
BUYS
15
SELLS
11
TOTAL VALUE
$922.8K
COMPANIES
2
ACTIVE SINCE
May 2023
HOLDINGS NOW
148,502
AVG SELL PX
$13.99
TRADE KIND
SHOWING 26 / 26
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
10 backtested trades · 8 horizons · 15 pending
Forward-return performance of every backtestable P/S trade by Eric Crombez, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d10+70.00%-1.53%+0.94%-2.46%-0.58%—
14d10+90.00%-3.06%+1.57%-4.59%-2.69%—
30d10+90.00%-7.40%+2.74%-9.96%-11.51%—
60d10+60.00%-2.35%+4.50%-6.86%-9.51%—
90d10(1 pending)+55.56%-11.10%+8.61%-21.59%-22.24%—
180d10(3 pending)+57.14%-1.98%+15.82%-17.80%-32.02%—
1y10(4 pending)+100.00%-26.82%+20.01%-46.83%-50.40%—
2y10(7 pending)+100.00%-47.53%+41.48%-89.01%-87.17%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
RARE · 111,189 shares · as of May 5, 2026
027,79755,59583,392111,189202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 15 buys / 11 sellsCOVERAGE · 13 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ABEO
ABEONA THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
26,143$5.53$144.6K37,313May 15, 2026May 15, 2026 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE
EVP and Chief Medical Officer
344$24.96$8.6K111,189May 5, 2026May 6, 2026 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
59,952——59,952Apr 16, 2026Apr 20, 2026 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
34,674——110,975Apr 16, 2026Apr 20, 2026 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE
EVP and Chief Medical Officer
7,029$22.80$160.3K76,301Mar 2, 2026Mar 3, 2026 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
11,643——83,173Mar 1, 2026Mar 3, 2026 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
SALE
16,284$5.09$82.9K63,456Feb 2, 2026Feb 2, 2026 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
37,313——79,740Jan 26, 2026Jan 27, 2026 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
SALE
4,718$6.93$32.7K42,427Aug 14, 2025Aug 15, 2025 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE
EVP and Chief Medical Officer
520$39.24$20.4K71,530May 5, 2025May 5, 2025 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE
EVP and Chief Medical Officer
242$35.11$8.5K71,680Apr 21, 2025May 5, 2025 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE
EVP and Chief Medical Officer
8,945$42.10$376.6K71,922Mar 3, 2025Mar 4, 2025 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
16,813——65,244Mar 1, 2025Mar 4, 2025 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
14,971——80,215Mar 1, 2025Mar 4, 2025 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
30,246——30,246Mar 1, 2025Mar 4, 2025 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
36,101——47,145Jan 31, 2025Feb 3, 2025 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
11,044——11,044Aug 13, 2024Aug 14, 2024 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE
EVP and Chief Medical Officer
354$43.66$15.5K48,431May 2, 2024May 3, 2024 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE
EVP and Chief Medical Officer
142$44.10$6.3K48,785Apr 18, 2024Apr 19, 2024 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
19,400——49,912Mar 1, 2024Mar 5, 2024 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
34,200——34,200Mar 1, 2024Mar 5, 2024 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
2,351——2,351Mar 1, 2024Mar 5, 2024 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE
EVP and Chief Medical Officer
1,238$53.76$66.6K48,927Mar 1, 2024Mar 5, 2024 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
2,351——2,351Sep 27, 2023Sep 29, 2023 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
8,362——8,362May 1, 2023May 2, 2023 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
4,658——30,512May 1, 2023May 2, 2023 ↗View →
Other insiders · RARE
Loading peer insiders…
About this filer
CIK 0001653052
ROLE
EVP and Chief Medical Officer
PRIMARY
RARE
COMPANIES
2
ACTIVE SINCE
May 2023
MARKETPEEL · /INSIDER/0001653052DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback